Quie P G
Rev Infect Dis. 1987 Jan-Feb;9(1):189-93. doi: 10.1093/clinids/9.1.189.
Since serious infections are major complications in patients with fewer than 200 phagocytic cells per microliter or in patients with dysfunctional phagocytes, granulocyte transfusions have been used in an attempt to improve clinical outcome. After two decades of trial and clinical use, the role of granulocyte transfusions for therapy of serious infections has not been clearly established. The methods of harvest, storage, and transfusion of granulocytes are acceptable; however, the quantities that are obtained from donors restrict numbers of cells that may be transfused. Limited clinical response has diminished enthusiasm for the use of granulocyte transfusions as therapy, and their use as prophylaxis has been ineffective. Reported clinical data suggest that patients with persisting granulocytopenia with sepsis due to gram-negative bacteria and patients with chronic granulomatous disease with life-threatening infections unresponsive to aggressive antimicrobial therapy may benefit from granulocyte transfusions.
由于严重感染是每微升吞噬细胞少于200个的患者或吞噬细胞功能异常患者的主要并发症,因此已使用粒细胞输注来试图改善临床结局。经过二十年的试验和临床应用,粒细胞输注在严重感染治疗中的作用尚未明确确立。粒细胞的采集、储存和输注方法是可以接受的;然而,从供体获得的数量限制了可输注的细胞数量。有限的临床反应降低了将粒细胞输注用作治疗方法的热情,并且其用作预防措施一直无效。报告的临床数据表明,因革兰氏阴性菌引起败血症而持续粒细胞减少的患者以及患有慢性肉芽肿病且对积极抗菌治疗无反应的危及生命感染的患者可能从粒细胞输注中获益。